RELIEF THERAPEUTICS Holding SA announced positive 12-month stability data for the liquid and lyophilized preparations of RLF-100 ®, intended for intravenous and inhaled administration.
CathVision announced initial patient enrollment of a follow-on clinical study to demonstrate the value of the Signal Complexity™ algorithm at OLV Hospital Aalst in Belgium led by Dr. Tom De Potter.1 The first patient has been enrolled.
AbbVie announced the European Commission approved RINVOQ® as the first oral Janus Kinase inhibitor for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
argenx SE and Genmab A/S announced that argenx and Genmab have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeutic areas.
Otsuka Pharmaceutical Development & Commercialization, Inc., and Lundbeck Pharmaceuticals LLC announce the Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. FDA met to discuss the supplemental New Drug Application of REXULTI® for the treatment of agitation associated with Alzheimer’s dementia.
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, presented promising preclinical data on its novel oncolytic virus TG6050, at the American Association for Cancer Research Annual Meeting, April 14-19, 2023.
Abbisko announced the results of five latest preclinical studies at the 2023 American Association for Cancer Research annual meeting.
Abbisko presents the research results of 5 programs at the 2023 AACR Annual Meeting Read More »
As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innovative biopharmaceuticals to patients worldwide with 5 products launched in China.
Henlius Achieved Steep Revenue Growth in Q1 2023, Core Products Sales Surged Read More »
Complement Therapeutics GmbH, a preclinical stage biotechnology company developing novel therapeutics for complement mediated diseases, announced the completion of a €72 million Series A financing.
Clinical results for experimental treatments in Alzheimer’s, ALS and more are expected over the coming months. BioSpace highlights a few of the more highly anticipated datasets.
